AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04193566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Forxiga
Description: Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf.~Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin.
Study NCT00414297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECP Therapy
Description: application of ECP Therapy to CAD Patients
Study NCT00414297 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ECP Therapy
Description: application of ECP Therapy to CAD Patients
Study NCT02983708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (mPBMC)
Study NCT02983708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: G-CSF
Study NCT02983708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study NCT02983708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02230397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: plantaricin a (active product)
Description: Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
Study NCT02230397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: placebo product
Description: Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
Study NCT01624519 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Lactate Analysis
Description: When an arterial lactate is deemed to be necessary as part of ICU management, a central venous and peripheral venous sample will also obtained within 5 minutes. All of the samples will be analyzed using the same analyzer as quickly as possible.
Study NCT04165538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombelastograph and surgical timing
Description: Patients in the TEG group will undergo a Thrombelastograph test after admission, and the timing of operation will be determined according to the results of the test, that is, 1 day, 3 days and 5 days later respectively for patients with ADP-induced platelet-fibrin clot strength (MAADP) of > 50 mm, 30-50 mm and \< 30 mm. For Non-TEG patients, the drug withdrawal time is determined by the doctor in charge according to the clinical routine, generally about one week.
Study NCT01152203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Starting dose of 70 mg/m\^2 by vein on Days 1 and 2 of a 28 day cycle
Study NCT01152203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein on Days 1 \& 15 of every 28 day cycle
Study NCT05976399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Massage
Description: In participants in the CTM group, the treatment was started with the sacral region called the basic region and the whole back was treated. Pulls in the interscapular region were more intense than in other regions. After the interscapular region, the cervical, clavicular, and facial regions were also included in the treatment. Both short and long pulls were used according to the region during CTM. The applications first started with the basic region and then progressed to the lower thoracic, scapular, and interscapular regions. Then, the cervical and clavicular regions were treated. In each region, the applications were performed three times on each of the right and left sides. While positioning the patients, we paid attention to their privacy and the temperature of the room where the treatment was carried out. A total of 12 sessions, which were conducted 2 days a week and took 6 weeks, were performed.
Study NCT05976399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymph Drainage
Description: The patients, who had filled out their pain diary before and submitted a consent form, were first evaluated before the treatment and then they lay on their back with their neck area open, paying attention to the protection of their privacy. Hand strokes, one of the basic techniques applied for treatment, were planned in accordance with the anatomy and physiology of the lymphatic system. MLD was applied to the lateral neck and face region in 5-7 repetitions so that the lymph collectors could give an adequate reaction to the application. The treatment was performed 2 days a week for 6 weeks, with a total of 12 sessions. Each session lasted 45 minutes.
Study NCT04276038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B-Cure laser pro
Description: The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2. The device is used at home and is self-applied by the patient. The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment. The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).
Study NCT04276038 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: B-Cure laser pro
Description: The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2. The device is used at home and is self-applied by the patient. The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment. The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).
Study NCT00717457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: 5mg twice daily for 4 weeks followed by 10mg twice daily
Study NCT00717457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg once weekly
Study NCT00717457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg once weekly for 4 weeks followed by 20mg once weekly
Study NCT01836419 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic LMA insertion
Study NCT01836419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: classic LMA insertion
Study NCT05123456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiography
Description: Comparative X-ray of the single knee at 30 ° flexion.
Study NCT02620345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone M ( case 1 )
Description: Dydrogesterone Multivitamin nature~* Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature.~* 1tablet/24 hours/day (to 4 weeks after postpartum)
Study NCT02620345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone M ( case 2 )
Description: Dydrogesterone Multivitamin nature~* Fibroids/ Women of Reproductive age ( discovered fibroids )~* 1tablet/24 hours/day ( from discovered fibroids through 6 months)
Study NCT01229020 — intervention group
Intervention type: OTHER
Intervention: Observational study - no intervention
Description: Observational study - no intervention. Patients underwent VRI recordings and routine V/Q scan.
Study NCT00469586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, pre-prandial, inhalation.
Study NCT00469586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 2000 mg/day.
Study NCT00469586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Tablets, 4 mg/day.
Study NCT00469586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, post-prandial, inhalation.
Study NCT04659109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glenzocimab
Description: IV administration as a sterile product
Study NCT04659109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV administration
Study NCT01240005 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCIK
Description: Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.
Study NCT04442906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).
Study NCT04442906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug)
Study NCT04442906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Group B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline.
Study NCT01616732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: TU im
Study NCT01616732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo im
Study NCT01695551 — intervention group
Intervention type: OTHER
Intervention: Data Collection Forms
Description: Participants will be asked questions relating to pre-procedure items and be asked to complete an MMSE. Subjects receive standard of care surgery. Data collected from procedures before, during and after surgery.
Study NCT02401126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate supplementation
Description: Nitrate supplementation: concentrated nitrate-rich beetroot juice (2 x 70 ml/day; approximately 10 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days.
Study NCT02401126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: nitrate-depleted beetroot juice (2 x 70 ml/day; approximately 0.01 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days. The placebo juice is similar to the concentrated beetroot juice in appearance, texture, smell and taste and is obtained by removing nitrate ions from the latter.
Study NCT00500487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Management
Description: 12-session group intervention including affect management training as well as sexual health skills training.
Study NCT00500487 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Prevention Skills
Description: 12-session group intervention including sexual health skills training.
Study NCT00500487 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Promotion
Description: 12-session group intervention including health information on a variety of health topics.
Study NCT03372538 — intervention group
Intervention type: PROCEDURE
Intervention: cesarean section or cesarean hysterectomy
Description: upper segment cesarean section and or cesarean hysteroctomy
Study NCT03209882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TILS
Description: Continuous-wave laser of a specific wavelength (1064 nm) was administered to the participants' right forehead for 8 minutes. The laser power was 3.4 Watts.
Study NCT03209882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham
Description: The sham session consisted of administering the same laser to the participants' right forehead for totally 8 minutes. However, the laser power was turned to be 0 Watts.
Study NCT00344552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
Study NCT00094302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
Study NCT00094302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of spironolactone
Study NCT01029938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Covered stent
Description: Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
Study NCT01029938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coil
Description: Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
Study NCT04175951 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens
Description: Tecnis Eyhance is a monofocal IOL which give added intermediate vision without employing EDOF or multifocal technology and hence induces no glare and halos. Whereas monofocal IOLs such as RayOne do not give intermediate vision.
Study NCT00154102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Number of Cycles: until progression or unacceptable toxicity develops
Study NCT00154102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Description: Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
Study NCT00154102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Description: Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
Study NCT00628160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin 2-12 mg/24h intravenously in continuous infusion. Duration: until 24h after shock resolution.
Study NCT00628160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha adrenergic drugs
Description: Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution
Study NCT02218164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha-2b
Description: Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
Study NCT02218164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m\^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
Study NCT02218164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m\^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
Study NCT04167566 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Artemisinin Combination Therapy ACTs
Description: All participants will be tested using RDTs and all confirmed cases will be treated with ACTs. The ACT regimen use at each time will be the one the National Malaria Control Programme will be using at that particular moment.
Study NCT02173704 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero®
Description: Four doses administered in the anterolateral area of the right or left thigh.
Study NCT02173704 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine vaccines
Description: Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.
Study NCT01138072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: 200mg once daily
Study NCT01138072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 20 mg Simvastatin single dose
Study NCT01138072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20 mg atorvastatin single dose
Study NCT01138072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg rosuvastatin single dose
Study NCT02373332 — intervention group
Intervention type: OTHER
Intervention: omega-3 and -6 fatty acids and their 12-LOX oxylipins
Description: platelets from healthy subjects and T2DM patients will be isolated from their blood and treated with omega-3 and -6 fatty acids and their 12-LOX oxylipins of those fatty acids followed by assessment of protection from agonist-induced platelet activation and thrombosis
Study NCT03863730 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Profermin Plus, FSMP, probiotics
Description: Participants will have to supply their normal intake with Profermin Plus, FSMP, Prbiotics product twice every day for 24 weeks.~The product Profermin Plus® has changed its name to ReFerm®. The content of the product is unchanged. The change occurred after the clinical part of the study was completed.
Study NCT03863730 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin, dietary supplement
Description: Participants will have to supply their normal intake with the control product, Fresubin, dietary supplement twice every day for 24 weeks.
Study NCT04183881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab 210mg SC
Description: 210 mg, subcutaneous dosing, every 2 weeks
Study NCT03287050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV q 21 days
Study NCT03287050 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiation therapy (SBRT) that will commence not later than the initiation of the second cycle of pembrolizumab. SBRT dose and fractionation will be at the discretion of the treating radiation oncologist, and will be selected to respect the normal tissue tolerance of adjacent organs at risk.
Study NCT04589910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: diaphragm thickness and thickening fraction
Description: Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
Study NCT01147952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise training
Description: randomised to 12 weeks of exercise training up to three times weekly. Training will be interval training with active recovery, with 3 min intervals conducted 10bpm below angina threshold.
Study NCT01648010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-3 gel
Description: One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.
Study NCT01648010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-3 gel mixed with Mitomycin C (MMC)
Description: One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter
Study NCT00866242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a
Description: The challenge strain consists of freshly harvested Shigella flexneri 2a strain 2457T diluted in phosphate buffered saline to reach the desired inoculum Form: liquid Dose 10 to the 3rd power CFU in 1.0 ml Route: oral.